Tamer Hellou: Chromosome 1q Gain Signals High Long-Term Risk in AL Amyloidosis
Tamer Hellou, Advanced Hematology Clinical Fellowship at Mayo Clinic Rochester, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in American Journal of 0f Hematology, adding:
”Excited to share our newly published work in the American Journal of Hematology:
‘Chromosome 1q Gain Defines a Plasma Cell–Dominant Adverse-Risk Subtype in AL Amyloidosis With Inferior Long-Term Survival.’
In this study of 517 patients with newly diagnosed AL amyloidosis, +1q identified a distinct plasma cell–dominant phenotype, characterized by greater clonal burden and inferior long-term survival, while other high-risk cytogenetic lesions did not show the same adverse prognostic impact.
Importantly, despite good early hematologic and organ responses, patients with +1q remained at risk for poorer long-term outcomes, with its adverse impact becoming particularly evident beyond two years, highlighting the importance of long-term vigilance even in patients who respond well initially.
Grateful to Eli Muchtar and all my colleagues and collaborators at Mayo Clinic for their guidance and contributions to this work.”
Title: Chromosome 1q Gain Defines a Plasma Cell–Dominant Adverse-Risk Subtype in AL Amyloidosis With Inferior Long-Term Survival
Authors: Tamer Hellou, Estefania Gauto Mariotti, Ahmed Alnughmush, Linda B. Baughn, Prashant Kapoor, Saurabh Zanwar, Shinichiro Suzuki, Maximilian J. Steinhardt, Daniel G. Packard, Taxiarchis V. Kourelis, Francis K. Buadi, David Dingli, Suzanne R. Hayman, Nelson Leung, Yi Lisa Hwa, Amie Fonder, Miriam Hobbs, Rahma Warsame, Joselle Cook, Moritz Binder, Nadine Abdallah, Yi Lin, Ronald S. Go, Robert A. Kyle, S. Vincent Rajkumar, Wilson I. Gonsalves, Shaji K. Kumar, Morie A. Gertz, Angela Dispenzieri, Eli Muchtar

Stay updated on all scientific advances with Hemostasis Today.
-
Aug 26, 2026, 17:09Kemal Karaagac: NOACs May Offer Cognitive and Clinical Benefits in AF With Alzheimer’s Disease
-
Aug 26, 2026, 16:53Chokri Ben Lamine: Antiphospholipid Syndrome After Kidney Transplantation
-
Aug 26, 2026, 16:32Kai Rejeski: Why TP53 Mutations May Define a Higher-Risk CAR-T Population
-
Aug 26, 2026, 16:20Ons Marsit: Impact of Electroanatomical Mapping on Pentaspline Pulsed Field Ablation
-
Aug 26, 2026, 16:18Sam Mbunya: Celebrating Cyrus Njuguna Githinji’s New Leadership Role in Haemophilia Care
-
Aug 26, 2026, 15:48Melissa Hollo: Postpartum Depression is More Than the “Baby Blues”
-
Aug 26, 2026, 15:46Raghavendra Rao: The Link Between Neuropathy and Chronic Venous Disease
-
Aug 26, 2026, 15:43Laurent Bertoletti: Long Term Benefits and Safety of Rehabilitation in Pulmonary Arterial Hypertension
-
Aug 26, 2026, 15:04Sequential Efgartigimod and Eltrombopag Achieve Durable Response in Refractory ITP – Platelets Journal